These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34186166)

  • 1. An adverse outcome pathway on the disruption of retinoic acid metabolism leading to developmental craniofacial defects.
    Menegola E; Veltman CHJ; Battistoni M; Di Renzo F; Moretto A; Metruccio F; Beronius A; Zilliacus J; Kyriakopoulou K; Spyropoulou A; Machera K; van der Ven LTM; Luijten M
    Toxicology; 2021 Jun; 458():152843. PubMed ID: 34186166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the quantification approach to a radiation relevant adverse outcome pathway for lung cancer.
    Stainforth R; Schuemann J; McNamara AL; Wilkins RC; Chauhan V
    Int J Radiat Biol; 2021; 97(1):85-101. PubMed ID: 32909875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case example of a radiation-relevant adverse outcome pathway to lung cancer.
    Chauhan V; Sherman S; Said Z; Yauk CL; Stainforth R
    Int J Radiat Biol; 2021; 97(1):68-84. PubMed ID: 31846388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an adverse outcome pathway for cranio-facial malformations: A contribution from in silico simulations and in vitro data.
    Metruccio F; Palazzolo L; Di Renzo F; Battistoni M; Menegola E; Eberini I; Moretto A
    Food Chem Toxicol; 2020 Jun; 140():111303. PubMed ID: 32251704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis.
    Verhoeven A; van Ertvelde J; Boeckmans J; Gatzios A; Jover R; Lindeman B; Lopez-Soop G; Rodrigues RM; Rapisarda A; Sanz-Serrano J; Stinckens M; Sepehri S; Teunis M; Vinken M; Jiang J; Vanhaecke T
    Toxicology; 2024 Jun; 505():153814. PubMed ID: 38677583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular Pathway and AOP Development Using Gene Network Analysis].
    Tanabe S; Hirose A; Whelan M; Yamada T
    Yakugaku Zasshi; 2020; 140(4):485-489. PubMed ID: 32238629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor.
    Becker RA; Patlewicz G; Simon TW; Rowlands JC; Budinsky RA
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):172-90. PubMed ID: 26145830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
    Becker RA; Ankley GT; Edwards SW; Kennedy SW; Linkov I; Meek B; Sachana M; Segner H; Van Der Burg B; Villeneuve DL; Watanabe H; Barton-Maclaren TS
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):514-37. PubMed ID: 25863193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children.
    Sachana M; Rolaki A; Bal-Price A
    Toxicol Appl Pharmacol; 2018 Sep; 354():153-175. PubMed ID: 29524501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A strategy towards the generation of testable adverse outcome pathways for nanomaterials.
    Murugadoss S; Vinković Vrček I; Pem B; Jagiello K; Judzinska B; Sosnowska A; Martens M; Willighagen EL; Puzyn T; Dusinska M; Cimpan MR; Fessard V; Hoet PH
    ALTEX; 2021; 38(4):580-594. PubMed ID: 34008034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing adverse outcome pathways on silver nanoparticle-induced reproductive toxicity via oxidative stress in the nematode Caenorhabditis elegans using a Bayesian network model.
    Jeong J; Song T; Chatterjee N; Choi I; Cha YK; Choi J
    Nanotoxicology; 2018 Dec; 12(10):1182-1197. PubMed ID: 30663905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case Study on Integrating a New Key Event Into an Existing Adverse Outcome Pathway on Oxidative DNA Damage: Challenges and Approaches in a Data-Rich Area.
    Huliganga E; Marchetti F; O'Brien JM; Chauhan V; Yauk CL
    Front Toxicol; 2022; 4():827328. PubMed ID: 35573276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of an Adverse Outcome Pathway Network by Bayesian Regression and Bayesian Network Modeling.
    Moe SJ; Wolf R; Xie L; Landis WG; Kotamäki N; Tollefsen KE
    Integr Environ Assess Manag; 2021 Jan; 17(1):147-164. PubMed ID: 32965776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse outcome pathways and linkages to transcriptomic effects relevant to ionizing radiation injury.
    Yu J; Tu W; Payne A; Rudyk C; Cuadros Sanchez S; Khilji S; Kumarathasan P; Subedi S; Haley B; Wong A; Anghel C; Wang Y; Chauhan V
    Int J Radiat Biol; 2022; 98(12):1789-1801. PubMed ID: 35939063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach.
    van Ertvelde J; Verhoeven A; Maerten A; Cooreman A; Santos Rodrigues BD; Sanz-Serrano J; Mihajlovic M; Tripodi I; Teunis M; Jover R; Luechtefeld T; Vanhaecke T; Jiang J; Vinken M
    J Biomed Inform; 2023 Sep; 145():104465. PubMed ID: 37541407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating fatty liver disease-associated adverse outcome pathways of perfluorooctane sulfonate using a systems toxicology approach.
    Kim M; Kim SH; Choi JY; Park YJ
    Food Chem Toxicol; 2023 Jun; 176():113781. PubMed ID: 37059384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an adverse outcome pathway for chemically induced hepatocellular carcinoma: case study of AFB1, a human carcinogen with a mutagenic mode of action.
    Moore MM; Schoeny RS; Becker RA; White K; Pottenger LH
    Crit Rev Toxicol; 2018 Apr; 48(4):312-337. PubMed ID: 29431554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the adverse outcome pathway concept for investigating developmental neurotoxicity potential of Chinese herbal medicines by using human neural progenitor cells in vitro.
    Klose J; Li L; Pahl M; Bendt F; Hübenthal U; Jüngst C; Petzsch P; Schauss A; Köhrer K; Leung PC; Wang CC; Koch K; Tigges J; Fan X; Fritsche E
    Cell Biol Toxicol; 2023 Feb; 39(1):319-343. PubMed ID: 35701726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoic acid exposure of the mouse on embryonic day 9 selectively spares derivatives of the frontonasal neural crest.
    Grant JH; Maggio-Price L; Reutebuch J; Cunningham ML
    J Craniofac Genet Dev Biol; 1997; 17(1):1-8. PubMed ID: 9211117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the Adverse Outcome Pathway Concept to
    Jarzina S; Di Fiore S; Ellinger B; Reiser P; Frank S; Glaser M; Wu J; Taverne FJ; Kramer NI; Mally A
    Front Toxicol; 2022; 4():864441. PubMed ID: 35516525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.